• Zera Intein Protein Solutions (ZIP) is specialized in the development of technologies for the production of peptides and recombinant proteins for both therapeutic and industrial interest, with applications in the biotechnological, pharmaceutical, veterinary and industrial sectors.
  • Both parties agreed as a mandatory irrevocably condition to trigger the transaction the event of signing a co-development and license agreement between ZIP and a leading multinational company, which occurred last April, 24. Under the terms of the agreement the multinational is granted a worldwide exclusive license for the final development and market of Splittera® technology for industrial purification of biological products.
  • The acquisition of this company, located in Barcelona and owned by Inveready Innvierte Biotech II, is valued at 1.6 million Euros

 

 May 3, 2016.  Bionaturis Group continues its expansion with the acquisition of the company Zera Intein Protein Solutions (ZIP), specialized in the development of technology for the production of peptides and recombinant proteins for application in the biotechnology, pharmaceutical, veterinary, and industrial sectors.

ZIP, founded in March 2015, inherited the main assets of Era Biotech, a company established in 2002 as a spin-off of the CSIC, in which approximately EUR 13 million were invested. ZIP, located in the Parc de Recerca in the Universitat Autònoma de Barcelona has a three people team and a rich portfolio of seven families of patents. The company commercializes its proprietary technologies Zera® and Splittera®, which facilitates the production and purification of difficult to express biological compounds and improve the production capacity of cellular systems. ZIP is owned by Inveready Innvierte Biotech II.

The acquisition of this company increases Bionaturis Group services portfolio and contributes to the international positioning as a partner of reference for the development of biological products for both human and animal health. “Bionaturis Group continues adding talent and state-of-the-art technology to raise our competitiveness and offer a wide range of solutions adapted to the requirements of our customers. With the incorporation of ZIP, the family of Bionaturis Group grows to three companies along with subsidiaries in different locations in Spain and abroad. At the same time we also value in a positive way the significant entrance of Inveready in the shareholding of Bionaturis due to the number of synergies that could be established both financially and industrially”, Bionaturis CEO, Victor Infante, has stated.

“We have accomplished the main goals we set last year when we acquired the assets, technologies and team from Era Biotech: supporting the company in an optimal way and progressing the development of our international business. This acquisiton by Bionaturis provides valuable profitability for our stockholders and leaves the company in the hands of a strategic partner that will benefit from the created technological value and will also generate additional value for their own (Bionaturis) stockholders”, the Inveready Investment Director, Sara Secall, has stated.

The acquisition process

ZIP acquisition will be made by means of a compensation of credits by a non-monetary capital increase which must follow the regulations affecting the transaction and that shall require the publication of the corresponding Capital Increase official document. Both parties agreed as a mandatory irrevocably condition to trigger the transaction the event of signing a co-development and license agreement between ZIP and a leading multinational company, which occurred last April, 24. Under the terms of the agreement the multinational is granted a worldwide exclusive license for the final development and market of Splittera® technology for industrial purification of biological products. The co-development and licensing agreement includes upfront, milestones and on-sales royalty payments. As a result of this transaction, valued at 1.6 million Euros, Inveready Biotech II is included from now on in the shareholding of Bionaturis with a participation rate over 5%.

About Inveready

Inveready Innvierte Biotech II is Inveready’s Venture Fund focused on early stage Life Science companies including mainly drug development, diagnostics, functional foods, devices and software. Inveready is one of the top Venture Capital Firms focused on early stage investments in Spain with five Venture Funds and 70 million euros under management.

About Bionaturis Group

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT). In addition to this new acquisition, Bionaturis Group has other two locations in Spain (Bionaturis and Biobide) and two subsidiaries in the USA and China.

 

TO DOWNLOAD DE PRESS RELEASE, PLEASE CLICK HERE

 

 www.bionaturis.com

www.zipsolutions.cat

 

For further information:                                                        

 Bionaturis Press

Virginia Montero

+34 856 818 424 / 655 311047

press@bionaturis.com